1. Introduction {#sec1}
===============

The protozoan parasite *Leishmania infantum* causes visceral leishmaniasis, a grave systemic disease that affects the spleen, liver, and bone marrow, leading to weight loss, anemia, and even death if left untreated ([@bib54]; [@bib50]). *Leishmania* are intracellular parasites with a promastigote and an amastigote form, found in the sandfly vector and vertebrate host, respectively ([@bib14]). Dogs serve as the main reservoir for infection ([@bib1]). With over 500,000 new cases of visceral leishmaniasis every year, this widespread disease is responsible for a significant health, psychosocial, and economic burden around the world ([@bib54]; [@bib50]).

Leishmaniasis has long been treated with antimonial drugs; first trivalent antimonials (Sb^III^), and later with the less toxic pentavalent antimonials (Sb^V^) ([@bib36]). The limited arsenal of available anti-leishmanial therapies coupled with the lack of an effective human vaccine make antimonials a first-line treatment still today -- despite their harmful side effects ([@bib36]; [@bib39]; [@bib37]). Resistance has become rampant in the field, rendering these drugs virtually ineffective against visceral leishmaniasis in certain areas of the world ([@bib25]; [@bib51]; [@bib46]).

The mechanism of action of antimonial drugs against *Leishmania* remains ambiguous, further complicating the fight against drug resistance ([@bib36]; [@bib21]; [@bib13]). Evidence suggests that pentavalent antimony (Sb^V^) is actually a prodrug, reduced to the active trivalent form (Sb^III^) in the macrophage and/or parasite ([@bib37]). Resistance mechanisms likely rely on decreased accumulation of antimony within the parasite (either through increased efflux or reduced uptake) ([@bib36]; [@bib37]). Early experiments demonstrated the presence of an efflux pump in the membrane of *L. tarentolae* that allowed extrusion of metals conjugated to thiols, and similar systems were later observed in *L. infantum* and *L. panamensis* ([@bib37]; [@bib8]). Although metal resistance in *Leishmania* spp. is multifactorial, the ATP-binding cassette protein MRPA has been shown to be implicated through recognition of thiol-conjugated metals and subsequent sequestration near the flagellar pocket for later exocytosis and/or extrusion outside the cell ([@bib21]; [@bib10]). Gene amplification is a frequent phenomenon in metal-resistant *Leishmania* in response to antimonial drug pressure; amplifications have been reported both intrachromosomally and as part of amplicons ([@bib33]; [@bib16]; [@bib23]; [@bib18]). Amplifications of *mrpA*, often identified within circular amplicons in antimony-resistant strains, have been extensively characterized ([@bib23]; [@bib32]). However, while an *mrpA*^*−/−*^ has been achieved in *L. tarentolae* ([@bib40]), there is no available literature describing the properties of a null *mrpA* mutant in human pathogenic *Leishmania*.

The goal of this study was to complete an in-depth exploration of the effects caused by the disruption of the *mrpA* gene in *L. infantum*, including its effect on parasite survival, impact on infectivity, and response to antimony sensitivity and selection. This information is critical to being better equipped in the fight against drug-resistant *Leishmania* by furthering knowledge of one of the many mechanisms these parasites use to survive in the presence of drugs.

2. Material and methods {#sec2}
=======================

2.1. *Leishmania* cultures {#sec2.1}
--------------------------

Wildtype parasites (WT), as well as the different mutants (e.g. nulls and overexpressors), were cultured as promastigotes at 25 °C in SDM-79 medium supplemented with 10% heat inactivated fetal bovine serum (FBS) and 5 μg/mL hemin. THP-1 cells (ATCC T1B-202) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 IU of penicillin/mL, and 100 μg of streptomycin/mL. Prior to infection, log-phase THP-1 cells were differentiated by incubation for 2 days in RMPI 1640 medium containing 20 ng/mL of phorbol myristate acetate (PMA) (Sigma).

2.2. Genomic modifications {#sec2.2}
--------------------------

### 2.2.1. mrpA null mutant {#sec2.2.1}

The *L. infantum mrpA* (LinJ.23.0290) null mutant (*mrpA*^*−/−*^) was obtained by targeted gene replacement. *mrpA* flanking regions were amplified from *L. infantum* 263 WT genomic DNA and fused to the puromycin acetyltransferase (*puro*) gene using a PCR fusion-based method. Briefly, the 5′UTR of *mrpA* was amplified using primers MRPA_A and MRPA_B, which includes a tail of 25 nucleotides complementary to the *puro* gene (see primer sequences in [Table S1](#appsec1){ref-type="sec"}). The *puro*information is critical to being better equipped ORF was amplified with primers MRPA_C and MRPA_D, which includes a tail of 25 nucleotides complementary to the 3′UTR of *mrpA*. The 3′UTR of *mrpA* was amplified using primers MRPA_E and MRPA_F. The 5′UTR of *mrpA* was then ligated to the puromycin resistance marker gene by PCR using primers A and D, information is critical to being better equipped giving the fragment 5′UTR-*puro* with a tail corresponding to the first 25 bases of the 3′UTR of *mrpA*. The marker gene was fused with the 3′UTR of *mrpA*, forming *puro*-3′UTR using primers C and F. The fragment 5′UTR-*puro* was then fused to the *puro*-3′UTR by PCR using primers A and F yielding the recombination cassette 5′UTR-*puro*-3′UTR. 10 μg of the 5′UTR-*puro*-3′UTR linear fragment were transfected by electroporation into *L. infantum* WT to replace both *mrpA* alleles. Recombinants were selected in the presence of 200 μg/mL of puromycin dihydrochloride (Wisent). After 4--5 passages, cells resistant to the drug selection were cloned in SDM-Agar plates (1%), also in the presence of 200 μg/mL puromycin. The *puro/puro* substitution of the *mrpA* gene was confirmed by PCR analysis of the recombinants and Southern blot. Two different PCRs were used: internal PCR was performed using primer set aa' that amplifies a 200-bp *mrpA*-specific region; external PCR was performed using a forward primer located in the *mrpA* 5′ flanking region with a reverse primer in the *mrpA* 3′ flanking region (primer set bb').

### 2.2.2. mrpA addback and overexpressor mutants {#sec2.2.2}

Genes *mrpA* (LinJ.23.0290)*, ABCC1* (LinJ.23.0230), *ABCC2* (LinJ.23.0240) and *sat* (LinJ.34.2710) were amplified from *L. infantum* genomic DNA using compatible primer pairs (see [Table S1](#appsec1){ref-type="sec"}) and PCR fragments were ligated into pGEM T-easy (Promega) to confirm the quality of the insert by standard sequencing. PCR fragments were then cloned in the *Leishmania* expression vector pSP72 α*hyg*α ([@bib38]), which contains the gene hygromycin phosphotransferase (*hyg*), a selectable marker in *Leishmania*. A total of 20 μg of plasmid DNA for episomal expression, either the empty vector (mock) or carrying the genes of interest, were transfected into *L. infantum* WT and *mrpA*^−/-^ promastigotes by nucleofection, as previously described ([@bib13]). Selection was achieved in the presence of 300 μg/mL hygromycin.

2.3. Mutant selection {#sec2.3}
---------------------

Five *L. infantum* puro/puro *mrpA*^−/-^ Sb-resistant mutants (*mrpA*^−/-^ CL1 to *mrpA*^−/-^ CL5) were independently selected from *mrpA*^−/-^ in 25 cm^2^ flasks containing 5 mL SDM-79 medium supplemented with 10% heat inactivated fetal bovine serum (FBS) and 5 μg/mL hemin in the presence of increasing Sb^III^ concentrations. Potassium antimonyl tartrate (Sigma-Aldrich, St Louis, MO, USA) was used as the source of Sb^III^. The stepwise drug selection ranged from 3 μM up to 180 μM of Sb^III^. Last-level *mrpA*^−/-^ Sb-resistant mutants were grown in the absence of drug pressure for 20 passages to revert resistance (rev).

2.4. Drug susceptibility assays {#sec2.4}
-------------------------------

Antileishmanial values in promastigotes were determined by monitoring the growth of parasites after 72 h of incubation at 25 °C in the presence of increasing antimony concentrations, by measuring A~600~ using a Cytation 5 machine (BioTek, USA). EC~50~ against antimony was evaluated in *in vitro* infections using a *luc*-expressing episomal vector (pSP1.2 *luc αhygα*) and PMA-differentiated THP-1 cells as previously described ([@bib12]). Briefly, PMA-differentiated THP-1 macrophages were infected with stationary-phase parasites at a ratio of 18:1, for 2 h at 37 °C in a 5% CO~2~ atmosphere. Cells were maintained in drug-free medium for 48 h, after which infected cells were either left untreated or were treated with increasing concentrations of Sb^V^ (Sodium Stibogluconate, Calbiochem) for 96 h at 37 °C. At this point, THP-1 cells were washed, and luciferase activity was determined using a Cytation 5. Drug-efficacy assays for both promastigotes and macrophage-infecting amastigotes were performed with at least three biological replicates from independent cultures (n = 3). EC~50~ values were calculated based on dose-response curves analysed by non-linear regression with GraphPad Prism 8.0 software (GraphPad Software, La Jolla California, USA). An average of at least three independent biological replicates was performed for each determination. Statistical analyses were performed using unpaired two-tailed t-tests. A *p* value \< 0.05 was considered statistically significant.

2.5. Whole genome sequencing {#sec2.5}
----------------------------

Genomic DNAs were prepared from a mid-log phase clonal culture of each mutant. Fifty nanograms of purified gDNA were used for paired-end library preparation using Nextera™ DNA Sample preparation kit (Illumina) according to the manufacturer\'s instructions. The size distribution of Nextera libraries was validated using an Agilent 2100 Bioanalyzer and High Sensitivity DNA chips (Agilent Technologies). Sequencing libraries were quantified with the QuantiFluor® dsDNA System and sequenced using an Illumina HiSeq system at a final concentration of 8 pM. An average genome coverage of over 50-fold was achieved for each *L. infantum mrpA*^−/-^ Sb-resistant mutant. This approach allowed identification of point mutations when compared with the reference genome sequence of *L. infantum* JPCM5 (TriTrypDB [version](tritrypdb:version){#intref0010} 8.0) ([@bib2]) and *L. infantum* 263 WT ([@bib47]). Sequence reads were aligned to the *L. infantum* JPCM5 genome using the software bwa-mem ([@bib11]). The maximum number of mismatches was 4, the seed length was 32, and 2 mismatches were allowed within the seed. Read duplicates were marked using Picard (<http://broadinstitute.github.io/picard>), and GATK was applied for indel realignment and SNP and InDel discovery ([@bib28]; [@bib7]) in *L. infantum mrpA*^−/-^ Sb-resistant mutants. PCR amplification and conventional DNA sequencing verified all putative point mutations detected by whole genome sequencing. Copy number variations (CNVs) were derived from read depth coverage by comparing the coverage of uniquely mapped reads between *L. infantum mrpA*^−/-^ Sb-resistant mutants and *L. infantum* 263 WT in small non-overlapping genomic windows (5 kb) for the 36 chromosomes (normalized to the total number of uniquely-mapped reads for each strain) ([@bib6]). Several python and bash scripts were created to further analyse the data. The sequence data for *L. infantum mrpA*^−/-^ Sb-resistant mutants is available at the NCBI BioProject (<https://www.ncbi.nlm.nih.gov/bioproject/>) under study accession PRJNA599612 and sample accessions SAMN13762311, SAMN13762312, SAMN13762313, SAMN13762314, SAMN13762315, SAMN13762316, SAMN13762317, SAMN13762318, SAMN13762319, SAMN13762320, corresponding to *mrpA*^*−/−*^ Sb-resistant CL1 20 × , CL2 20 × , CL3 20 × , CL4 20 × , CL5 20 × , CL1 60 × , CL2 60 × , CL3 60 × , CL4 60 × and CL5 60 × , respectively.

2.6. PFGE and southern blot {#sec2.6}
---------------------------

Molecular karyotype was obtained from *L. infantum* WT, *mrpA*^−/-^, *mrpA*^−/-^ Sb-resistant mutants, and revertants by separation of chromosomes through pulse field electrophoresis. 10^8^ mid-log phase parasites were embedded in low melting point agarose blocks, digested with proteinase K, and electrophoresed in a contour-clamped homogenous electric field apparatus (CHEF Mapper, Bio-Rad, Hercules, CA, USA). The blocks were mounted in 1% agarose gel and electrophoresed in 0.5x Tris-Borate-EDTA running buffer at 5 V cm^−1^ with a 120° separation angle at 14 °C for 30 h. A range of 150--1500 kb was applied for a wide chromosomal separation, resolving most *Leishmania* chromosomes in a single molecular karyotype gel. *Saccharomyces cerevisiae* chromosomes were used as a DNA size marker (Bio-Rad, Hercules, CA, USA). For Southern blots, genomic DNA was isolated using DNAzol reagent (Life Technologies, Carlsbad, CA, USA) following the manufacturer\'s instructions, then digested with the *Asc*I restriction enzyme (New England Biolabs Inc, Ipswich, MA, USA). Digested genomic DNA or PFGE-derived molecular karyotype was transferred by capillarity onto nylon membranes (Hybond-N^+^, Amersham Pharmacia Biotehc, Sunnyvale, CA, USA) and cross-linked with a crosslinker. Blots were hybridized with \[α-^32^P\] dCTP-labeled DNA probes according to standard protocol.

3. Results {#sec3}
==========

3.1. *mrpA* is not essential for *L. infantum* survival or infectivity but is key to modulation of parasite antimony sensitivity {#sec3.1}
--------------------------------------------------------------------------------------------------------------------------------

The gene coding for the puromycin acetyltransferase (*puro*) was cloned between the 5′- and 3′- *L. infantum mrpA* flanking regions and the linear PURO construct was transfected by electroporation. Instead of using a second selectable marker for substituting the second *mrpA* allele, we decided to explore the possibility of a single round of targeted gene replacement followed by selection for loss of heterozygosity ([@bib17]) by increasing by 2.5 fold the final puromycin-selection pressure. As depicted in [Fig. 1](#fig1){ref-type="fig"}A, hybridization with a 5′UTR probe should lead to 6.5 and 2.4 kb *Asc*I-*Asc*I bands in the WT and *puro*/*puro mrpA*^−/-^ parasites, respectively. As demonstrated in [Fig. 1](#fig1){ref-type="fig"}B (lane 2), we were able to generate a homozygous *puro*/*puro mrpA*^−/-^ line, as no signal for the WT *mrpA* allele at 6.5 kb was detected for the mutant. This result was further confirmed by whole-genome sequencing of the *mrpA*^−/-^ strain, as well as two PCR experiments ([Fig. 1](#fig1){ref-type="fig"}C): one targeting 200 bp within the gene (aa') and another targeting the whole *mrpA* ORF using +30 nucleotide external primers (bb'). Once the *mrpA*^−/-^ genotype was confirmed, puromycin-selection was not further continued.Fig. 1***mrpA* gene inactivation in *L. infantum*. (A)** Schematic representation of the *mrpA (LinJ.23.0290)* locus in *L. infantum* before and after integration of the inactivation cassette *PURO.* Relevant *Asc*I restriction sites (S) and size of digested fragments are shown. **(B)** Southern blot analysis with genomic DNAs digested with *Asc*I and probed with \[α-^32^P\]-dCTP-labelled 200 bp of 5′ *mrpA L. infantum* coding region. Lane 1, *L. infantum* WT; lane 2, *L. infantum puro/puro mrpA* null mutant; **(C)** PCR analyses (internal and external) for the confirmation of the correct substitution of the *mrpA* gene by the *PURO* cassette. Lane 1, *L. infantum* WT; lane 2, *L. infantum puro/puro mrpA* null mutant; **(D)** Phenotypic evaluation of the *L. infantum mrpA*^*−/−*^ mutant. EC~50~ values for Sb^III^ and Sb^V^ were determined for the promastigote and amastigote forms of the WT, null mutant and add-back lines. Data are the mean ± SD of three biological replicates. Differences were statistically evaluated by unpaired two-tailed t-test (*∗∗∗p ≤ 0.001*).Fig. 1

Experimental dose-response assays with the *mrpA*^−/-^ strain revealed an antimony hypersensitive phenotype in both promastigotes ([Fig. 1](#fig1){ref-type="fig"}D left panel; 20-fold Sb^III^ EC~50~ shift (P ≤ 0.001)) and macrophage-infecting amastigotes ([Fig. 1](#fig1){ref-type="fig"}D right panel; 2.6-fold Sb^V^ EC~50~ shift (*P* ≤ 0.001)). Transfection of the *mrpA* gene as part of an episomal vector in the *mrpA*^−/-^ strain resulted in a complete recovery of the WT phenotype.

3.2. Selection of *mrpA*^−/-^ cells for antimony resistance {#sec3.2}
-----------------------------------------------------------

Selection of MRPA-independent Sb-resistant mutants began at 1 × EC~50~ value for the *mrpA*^−/-^ strain (3.2 μM) up to 60 × IC~50~ (180 μM), which is approximately 2.5-fold the EC~50~ of the WT parental line. The selection procedure was fast (3 subsequent passages per drug concentration), and cells rapidly adapted to growing concentrations of Sb. All five clones reached the final selection step at 60 × EC~50~. In order to follow the evolution of the resistant phenotype for each clone, dose-response assays were conducted at passage 3 (P3) for 1 × , 4 × , 10 × , 20 × and 60 × EC~50~ selection steps. As depicted in [Fig. 2](#fig2){ref-type="fig"}, all five clones reached similar EC~50~ values at selection step P3 10 × EC~50~, with clones CL1 and CL2 displaying slightly higher values (23 and 20 μM, respectively). While these two clones showed a great increase in EC~50~ values at selection step P3 20 × EC~50~ (48 and 63 μM, respectively), clones CL3, CL4 and CL5 remained with values around 20 μM. Once the final selection step was reached (P3 60 × EC~50~), clones were reevaluated for sensitivity against antimony. Clones CL1 and CL2 demonstrated the highest EC~50~ values (105 and 141 μM), higher than the EC~50~ value for the parental WT strain (approximately 65 μM). The other clones reached modest but significant increases in their EC~50~ values (CL3: 35; CL4: 48; and CL5: 38 μM), which represent a 6-fold mean increase compared to the unselected parental *mrpA*^*−/−*^ strain. Potentially different mechanisms of adaptation to Sb are being deployed by independent clones.Fig. 2**Phenotypic appraisal of the *mrpA***^***−/−***^**clones submitted to stepwise selection for antimony resistance.** EC~50~ values in promastigotes of the different *L. infantum mrpA*^*−/−*^ mutants at P3 for 1 × , 4 × , 10 × , 20 × and 60 × EC~50~ selection steps were determined by monitoring the growth of parasites after 72-h of incubation at 25 °C in the presence of increasing antimony concentrations, by measuring A~600~ using a Cytation 5 (BioTek, USA). Data are the mean ± SD of three biological replicates.Fig. 2

3.3. Exposure of *mrpA*^−/-^ mutants to increasing concentrations of Sb results in major changes in CNVs {#sec3.3}
--------------------------------------------------------------------------------------------------------

Whole-genome sequencing was conducted by Illumina next-generation sequencing on the five independent *L*. *infantum mrpA*^−/-^ Sb-resistant lines selected at 20 × and 60 × EC~50~, as well as the isogenic *L*. *infantum* WT line. For all strains, this produced genome assemblies of 31 Mb with a coverage depth of at least 50-fold.

Several cases of supernumerary chromosomes were observed in the *mrpA*^*−/−*^ Sb-resistant mutants ([Fig. 3](#fig3){ref-type="fig"} and Dataset S1), the majority of which had log~2~ *mrpA*^*−/−*^ Sb-resistant/WT read ratios close to 0.5. Parasites from the *Leishmania Leishmania* subgenus have predominantly disomic genomes, and this should thus represent a gain of one allele compared to WT parasites (going from 2 to 3 chromosome copies). Most supernumerary chromosomes were shared by the mutants; chromosomes 6 and 9 were consistently increased in all *mrpA*^*−/−*^ Sb-resistant mutants except CL4, chromosomes 18 (except in CL5 at 60 × ) and 23 were increased in all five mutants. Markedly, chromosome 23 passed from disomic to tetrasomic for CL5. Chromosome 8 was increased for clones CL1, CL3 and CL4; and chromosome 11 for clones CL1, CL4 and CL5. Finally, CL1, CL2 and CL4 gained a copy of chromosome 12, thus becoming pentasomic. There were no major differences between genome sequences at 20 × and 60 × , with the exception of several chromosome losses, which were consistent with the loss of one allele ([Fig. 3](#fig3){ref-type="fig"}, Dataset S1). These losses affected chromosome 31 in CL2, CL3 and CL5. Overall, CL3 was the most divergent clone and displayed the highest level of chromosome-level CNVs compared to the four other mutants ([Fig. 3](#fig3){ref-type="fig"}). However, this did not correlate with reduced Sb sensitivity.Fig. 3**Dynamics of aneuploidy of *L. infantum mrpA***^***−/−***^**during *in vitro* adaptation to antimony.** Heatmap representation of log~2~-transformed normalized Sb-resistant/unselected read ratio for all 36 chromosomes in the five independent *L*. *infantum mrpA*^−/-^ Sb-resistant lines selected at 20 × and 60 × EC~50~. Chromosomes were divided into non-overlapping 5 kb genomic windows and median *L*. *infantum mrpA*^−/-^ Sb-resistant/unselected reads ratios for each chromosome were normalized according to the total number of reads followed by log~2~-transformation (See Dataset S1 for further details).Fig. 3

Normalized read depth coverage allowed the identification of amplified and deleted genomic loci in the *mrpA*^*−/−*^ Sb-resistant mutants. These are characterized by punctuated series of adjacent genomic windows whose normalized read coverage varies compared to the WT baseline, as observed for chromosome 23 in more than one mutant (Dataset S2). In fact, for chromosome 23, the amplified region was large, covering 110 kb and 75 kb in mutants CL2 and CL5, respectively ([Fig. 4](#fig4){ref-type="fig"}A and B). This amplification starts at one subtelomeric end and encompasses the region where the *mrpA* gene was located before generation of the null mutant. This subtelomeric amplification was suspected to be a linear amplicon rather than an intrachromosomal tandem duplication due to its length, its location close to a telomere, and the increase in number of normalized reads. Beside the amplification, normalized read depth coverage was higher in the mutant for the entire length of the chromosome ([Fig. 4](#fig4){ref-type="fig"}B) and supported the increase in ploidy described above for chromosome 23 ([Fig. 3](#fig3){ref-type="fig"}). Markedly, while the change of ploidy for all five clones seems to have been achieved at 20 × ([Fig. 4](#fig4){ref-type="fig"}A), the 60 × selection step was required to induce the subtelomeric amplification observed for clones CL2 and CL5 ([Fig. 4](#fig4){ref-type="fig"}B). Hybridization of chromosomes separated by PFGE with probe-targeting gene LinJ.23.0220 (located nearby *mrpA* on chromosome 23) supported the NGS data and confirmed that two mutants had linear amplifications corresponding to the subtelomeric region of the chromosome ([Fig. 4](#fig4){ref-type="fig"}C, lanes 4 and 7). Regarding clone CL1, normalized read depth coverage of chromosome 23 revealed 2 peaks, which are also comprised in the subtelomeric amplifications observed for CL2 and CL5 ([Fig. 4](#fig4){ref-type="fig"}B). The first corresponds to the genomic region LinJ.23:65000-80000, which contains the partial ORF of LinJ.23.0230 (ABCC1) and the complete sequence of LinJ.23.0240 (ABCC2) (see chromosme 23 in Dataset S2); the second corresponds to *mrpA* gene-flanking regions, an artifact due to a duplication of the puro selectable marker within the 5′ and 3' UTRs of *mrpA*.Fig. 4**Extrachromosomal amplifications in *L. infantum mrpA***^**−/−**^**Sb-resistant mutants and phenotypic evaluation of the revertant strains. (A)** Log~2~-transformed 20 × Sb-resistant mutants/unselected reads ratios for non-overlapping 5 kb genomic windows on chromosome 23. Orange, CL1; Red, CL2; Grey, CL3; Purple, CL4; and Green, CL5. **(B)** Log~2~-transformed 60 × Sb-resistant mutants/unselected reads ratios for non-overlapping 5 kb genomic windows on chromosome 23. Orange, CL1; Red, CL2; Grey, CL3; Purple, CL4; and Green, CL5. *a*, amplified region in clones CL2 and CL5; *b*, gap in the sequencing reads resulting from the deletion of the *mrpA* gene. **(C)** Chromosomes were separated by PFGE and hybridized with a probe targeting gene LinJ.23.0220. Lanes: 1, molecular weight marker; 2, *L. infantum* WT; 3, unselected *L. infantum mrpA*^−/-^ CL2; 4, 60 × Sb-resistant CL2; 5, revertant CL2; 6, unselected *L. infantum mrpA*^−/-^ CL5; 7, 60 × Sb-resistant CL5; 8, revertant CL5. **(D)** EC~50~ values for Sb^III^ were determined for the promastigote forms of *L. infantum mrpA*^−/-^ Sb-resistant clones and their revertant (Passage 20 in absence of Sb pressure) counterpart lines by monitoring the growth of parasites after 72-h of incubation at 25 °C in the presence of increasing antimony concentrations, by measuring A~600~ using a Cytation 5 (BioTek, USA). Data are the mean ± SD of three biological replicates. Differences were statistically evaluated by unpaired two-tailed t-test *(∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001* between each *mrpA*^−/-^ Sb-resistant mutant and its derived revertant line; and ^**\#**^*p ≤ 0.05* between each revertant and the unselected *mrpA*^−/-^ parental cell line). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 4

3.4. Link between gene amplification and drug resistance {#sec3.4}
--------------------------------------------------------

To verify if linear DNA amplifications were reversible, CL2 and CL5 (as well as the other clones) were subcultured in the absence of Sb pressure for 20 passages. The chromosomes of the revertants of CL2 and CL5 were separated by PFGE with a probe targeting the gene LinJ.23.0220. Both clones lost their respective linear amplicon after 20 passages in the absence of Sb pressure (lanes 5 and 8 of [Fig. 4](#fig4){ref-type="fig"}C).

Next, the potential resensitization of clones after 20 passages in the absence of Sb pressure was evaluated phenotypically. As depicted in [Fig. 4](#fig4){ref-type="fig"}D, the EC~50~ values for all five clones were significantly reduced compared with their *mrpA*^*−/−*^ Sb-resistant counterparts. CL1 and CL2 showed the greatest shift in EC~50~ values with 3- and 5-fold decreases, respectively. Shifts for clones CL3, CL4 and CL5 were more modest but still significant. None of the revertants reached the levels of hypersensitivity demonstrated by the parental *mrpA*^*−/−*^ strain before stepwise selection.

We looked for genes that were both part of the linear amplicons identified in clones CL2 and CL5, and were present in the genomic region enriched in CL1 (LinJ.23:65000-80000), and noticed the presence of *ABCC1* and *ABCC2* genes ([@bib22]). Overexpression of *ABCC1 and ABCC2* was performed by stable episomal transfection in the *mrpA*^−/-^ background, but also in WT parasites ([Fig. 5](#fig5){ref-type="fig"}A). While ABCC1 did not yield a resistant phenotype, overexpression of ABCC2 caused a 2-fold reduction in Sb sensitivity in the *mrpA*^−/-^ strain. No effect was observed in the WT background for either ABCC1 or ABCC2 ([Fig. 5](#fig5){ref-type="fig"}A).Fig. 5**Functional analysis of ABCC1/ABCC2 overexpression and different mutations in the *sat* gene in Sb susceptibility. (A)** Impact of overexpression of the genes ABCC1 and ABCC2 on the Sb-sensitivity profile of both WT and *mrpA*^−/-^ lines. **(B)** Impact of overexpression of the *sat* gene, as well as three mutated versions, on the Sb-sensitivity profile of *mrpA*^−/-^ parasites. **(C)** Impact of overexpression of the *sat* gene and its three mutated versions on the Sb-sensitivity profile of WT parasites. Data are the mean ± SD of three biological replicates. Differences were statistically evaluated by unpaired two-tailed t-test (∗*p ≤ 0.05*, ∗∗*p ≤ 0.01*, ∗∗∗*p ≤ 0.001*).Fig. 5

3.5. Point mutations and role of a serine acetyltransferase in antimony resistance {#sec3.5}
----------------------------------------------------------------------------------

A search for point mutations revealed very few homozygous SNPs in any of the five *mrpA*^*−/−*^ Sb-resistant mutants (Dataset S3), and none within any known drug resistance-related ORF. Homozygous SNPs were located in genes coding for hypothetical proteins, with the exception of LinJ.35.0500, which codes for a large proteophosphoglycan protein often found mutated in our various sequencing screens. Genes coding for hypothetical proteins were not studied further, as there was no recurrence among mutants for these genes. Heterozygous SNPs were more frequent, so they were clustered according to the number of clones carrying mutations in the same ORF ([Supplementary Figs. S1 and S2](#appsec1){ref-type="sec"}; Dataset S3). Eight heterozygous SNPs were common to the 5 clones at both 20 × and 60 × . In all cases, exactly the same mutation was present. Given the high probability that our laboratory strain already carries these SNPs (absent in the reference strain), they were not further analysed. No SNPs were found by NGS in the *aqp1* gene, which, when mutated or deleted, leads to a reduction in antimony uptake by the parasite ([@bib30]). This was further confirmed by targeted PCR and sequencing of the *aqp1* ORF from all five clones at both 20 × and 60 × selection steps. In order to find potential SNP candidates, the different clones were examined for SNPs occurring in the same ORF but at different positions. Only one SNP located in gene LinJ.34.2710 (serine acetyltransferase *sat* gene) in clones CL1, CL2 and CL4 at the 60 × selection step fulfilled this requirement ([Supplementary Fig. S2](#appsec1){ref-type="sec"}). The mutations identified in the three *mrpA*^*−/−*^ Sb-resistant mutants by NGS and confirmed by targeted PCR were *sat*^*Q390K*^ for CL1, *sat*^*G321R*^ for CL2 and *sat*^*G325R*^ for CL4. Interestingly, the heterozygous SNPs in the *sat* ORF for CL1, CL2 and CL4 were lost from the populations of the clones when grown for 20 passages in the absence of antimony.

We overexpressed the three *sat* heterozygous mutations (as well as the WT version of the gene) in both *mrpA*^−/-^ ([Fig. 5](#fig5){ref-type="fig"}B) and WT backgrounds ([Fig. 5](#fig5){ref-type="fig"}C). Overexpression of the *sat*^WT^ copy did not confer further Sb resistance in the *mrpA*^−/-^ strain nor in the WT cell line. However, overexpression of all three mutated variants of the *sat* gene resulted in a significant decrease in Sb sensitivity in the *mrpA*^−/-^ strain: *sat*^*Q390K*^ (2.12-fold), *sat*^*G321R*^ (2.94-fold) and *sat*^*G325R*^ (3.23-fold). That said, only two of these three mutations, *sat*^*G321R*^ and *sat*^*G325R*^, had a significant effect on Sb susceptibility in the WT strain (1.62- and 1.99-fold, respectively).

4. Discussion {#sec4}
=============

Although the mode of action of Sb remains unclear, several mechanisms of drug resistance have been extensively described in *Leishmania* parasites, including modulation of Sb detoxification pathways ([@bib32]; [@bib55]), altered drug internalization ([@bib30]; [@bib27]), and increased efflux ([@bib34]). However, the most frequently reported mechanism of Sb resistance is the intracellular sequestration of Sb-thiol conjugates, mediated by ABC-transporter MRPA ([@bib14]; [@bib36]; [@bib25]; [@bib45]). In this study, in order to search for MRPA-independent mechanisms of drug resistance against Sb, we utilized a unique combination of targeted disruption of the *mrpA* gene, stepwise drug-resistance selection, and next-generation sequencing (NGS) in *L. infantum* parasites.

Firstly, we demonstrated that MRPA is not essential for the survival and infectivity of *L. infantum in vitro*. As suspected, sensitivity to Sb was greatly increased in the *mrpA*^*−/−*^ mutant. MRPA-deficient promastigotes demonstrated a 20-fold decrease in their EC~50~ value against Sb^III^. That said, *mrpA*^*−/−*^ amastigotes showed a modest 2.6-fold increase in sensitivity against Sb^V^. Of note, although *mrpA* is frequently found in promastigote drug screens, and validated as a drug resistance gene with intracellular parasites ([@bib10]), its role as an *in vivo* marker of Sb resistance is controversial since it\'s not always found to be amplified in drug-resistant clinical isolates ([@bib32]; [@bib31]; [@bib3]) but increased in *mrpA* CNVs was found to be the main driver of molecular preadaptation to antimony resistance in *L. donovani* ([@bib9]). Interestingly, two different gain-of-function screens using genomic overexpression libraries coupled to NGS (Cos-Seq) revealed a very pronounced enrichment of the *mrpA* gene in promastigotes progressively exposed to Sb^III^, but not in macrophage-infecting amastigotes exposed to Sb^V^ ([@bib14]; [@bib13]), showing that MRPA-independent Sb-resistance mechanisms can be deployed by the parasite.

In order to identify novel MRPA-independent Sb-resistance mechanisms, we evaluated the ability of five independent *L. infantum mrpA*^−/-^ clones to become resistant to Sb^III^. In this study, all five clones were able to significantly decrease their sensitivity to Sb in comparison to the parental *L. infantum mrpA*^−/-^ line, but only two clones (CL1 and CL2) were able to surpass the EC~50~ value calculated for the parental WT strain. These results point to different genomic adaptation mechanisms occurring in each of the five independent clones. As gene expression in *Leishmania* is regulated predominantly by gene dosage ([@bib25]; [@bib19]), we proceeded to identify CNVs and SNP events in the five clones at two different selection steps, 20 × and 60 × EC~50~ of the unselected *L. infantum mrpA*^−/-^ strain, by NGS ([@bib25]). Normalized read depth coverage identified several chromosomes in the *mrpA*^*−/−*^ Sb-resistant clones whose ploidy was altered compared to the unselected parental line. However, no common pattern among karyotypes was found (except for chromosomes 18, 23 and 31, which displayed common changes in CNVs for almost all the clones), which makes it difficult to establish a link between phenotypes and karyotype variations. This is not new as *Leishmania* chromosome ploidy in individual parasites is known to vary rapidly in response to changing environments, including routine cell culture, resulting in mosaic aneuploidy ([@bib49]; [@bib52]). A recent study identified major changes in chromosomal somy, gene expression and gene dosage driven by Sb^III^ in *L. braziliensis* ([@bib41]). Markedly, our results for chromosomes 4 (CL1 and CL3), 11 (CL1, CL4 and CL5), 14 (CL2 and CL3) and 23 (all the clones) are in line with those reported by Patino and co-workers ([@bib41]).

*Leishmania* accumulates Sb^III^ primarily through aquaglyceroporin AQP1, which is involved in volume regulation and osmotaxis ([@bib15]). Loss-of-function mutations in its ORF, as well as CNVs at the level of the subtelomeric region of chromosome 31 harboring the *aqp1* gene result in decreased Sb^III^ susceptibility ([@bib30]; [@bib35]; [@bib44]; [@bib20]). Sb-selection did not induce mutations in the *aqp1* gene in any of our *mrpA*^*−/−*^ Sb-resistant clones. However, CL2, CL3, and CL5 reduced the ploidy of chromosome 31 by one copy at 60 × EC~50~, which could result in decreased Sb uptake. This finding corroborates previous studies demonstrating that *Leishmania* parasites submitted to experimental Sb selection rely on aneuploidy as their first adaptation mechanism, even before emergence and eventual fixation of SNPs ([@bib33]; [@bib30]; [@bib29]).

Alternatively, chromosome 23, harboring the H locus in which *mrpA* is located ([@bib23]), was amplified in all five of our *mrpA*^*−/−*^ Sb-resistant clones, transitioning from a disomic to trisomic ploidy in CL1 to 4, and to a tetrasomic ploidy in CL5. Markedly, the subtelomeric region of chromosome 23 was further amplified in CL2 and CL5 in the form of two different linear amplicons. On the other hand, CL1 demonstrated major enrichment of a 15-kb genomic region comprising the partial sequence of LinJ.23.0230 (*ABCC1*) and the complete ORF of LinJ.23.0240 (*ABCC2*), which is also included in the linear amplicons detected for CL2 and CL5. While it has been shown that *mrpA* is the only gene within the H locus that contributes to Sb resistance when overexpressed ([@bib9]; [@bib24]; [@bib5]), we decided to evaluate the impact of ABCC1 and ABCC2 in the *mrpA*^*−/−*^ background. Overexpression of ABCC2 resulted in a 2-fold increase in *mrpA*^*−/−*^ tolerance to Sb; an alteration not seen in the WT. ABCC2 is part of the ABCC subfamily, a class of proteins known to be involved in detoxification of metals in *Leishmania* ([@bib21]; [@bib24]). In wild-type cells only the transfection of the ABCC family member MRPA (ABCC3) produces Sb resistance. However in *L. tarentolae* revertant cells with unknown factors contributing to resistance, ABCC4 and 5 were shown to produce resistance as well ([@bib24]). Here when MRPA is absent, cells become hypersensitive to Sb, and in this case we were able to show that ABCC2 contributes to resistance in this specific cellular context.

Amplicons generated from the H locus containing *mrpA* have previously been found to be unstable in the absence of Sb pressure ([@bib23], [@bib25]). Likewise, in our experiment, after 20 passages in the absence of Sb drug pressure, both CL2 and CL5 lost their respective linear amplicons and significantly reduced their tolerance to Sb. However, they did not fully recover the *mrpA*^*−/−*^ phenotype, suggesting that other mutations contribute to resistance. Indeed, our screen for potential SNPs involved in the Sb-resistant *mrpA*^*−/−*^ phenotype lead to the identification of three different heterozygous mutations (Q390K, G321R and G325R) in gene LinJ.34.2710 at 60 × EC~50~, each one in a different *mrpA*^*−/−*^ Sb-resistant clone. The gene LinJ.34.2710 encodes a serine acetyltransferase (SAT) which has recently been surmised to be involved in the two routes of *de novo* cysteine synthesis in *Leishmania* ([@bib26]). *L-*serine is conjugated with acetyl-CoA by SAT to form the intermediate product *O*-acetylserine, which is then converted to *L-*cysteine by cysteine synthase (CS). Cysteine is the precursor moiety for biosynthesis of GSH and trypanothione, which are the main cellular defense mechanisms against oxidative stress, involved in Sb detoxification ([@bib16]; [@bib18]; [@bib40]; [@bib48]). Our three clones displaying a mutation in the *sat* gene were also those exhibiting the highest EC~50~ against Sb after reaching the last step of selection ([Fig. 2](#fig2){ref-type="fig"}). These heterozygous SNPs were not fixed in the genome of the parasite as they disappeared, probably by allelic exchange, after 20 passages in the absence of Sb drug pressure, which also led to a great decrease in Sb tolerance of the revertant clones. Most likely cells in the population with a mutated *sat* were at a disadvantage when grown in the absence of Sb^III^. Likewise, in a clinical context, most of the known Sb-resistant mechanisms relying on CNVs and heterozygous mutations are reverted without drug pressure. However, reversion has not been achieved in the Indian subcontinent, where Sb-resistant *Leishmania* parasites remain highly prevalent despite discontinuing the use of Sb as first-line treatment. Imamura and co-workers identified a 2-nt insertion in the *aqp1* gene in 52 strains isolated from antimonial treatment failure patients ([@bib20]). Its dissemination could have been favored, even in the absence of Sb-based treatments, by an increased fitness of Sb-resistant parasites ([@bib9]; [@bib53]) and cross-selection through chronic exposure to arsenic-contaminated water ([@bib42], [@bib43]). In our case, we were not able to achieve a full recovery of the *mrpA*^*−/−*^ sensitive phenotype after 20 passages in absence of Sb^III^. This could be caused by different metabolic adaptations acquired during the selection process (*e.g.* changes in mitochondrial metabolism or in membrane fluidity ([@bib4])) that would require extended subculturing to be diluted in the resensitized population.

Our preferred method for studying the role of SAT mutations was episomal transfection of wild-type and mutated forms of the gene in the *mrpA*^*−/−*^ mutant and WT. All three mutations conferred resistance to the *mrpA*^*−/−*^, but only the two with the strongest phenotype induced a significant shift in EC~50~ value against Sb in the WT. Of note, all three mutations occurred within the predicted CoA binding site (cysE domain) of the protein (aa 224--390). SAT mutations may be leading to more efficient production of *O*-acetylserine or to more stable CS and SAT protein complex formation. In either case, the SAT/CS complex would be capable of providing more than the necessary amount of cysteine for biosynthesis of GSH, and thus trypanothione, which can bind to Sb to facilitate its elimination -- as well as counteract ROS formation ([@bib48]). Since SAT mutations could increase thiols (*e.g.* trypanothione and glutathione) through, by example, disabling of a regulatory site or negative feedback loop limiting such products, future work should evaluate the content of the different thiol species in the *mrpA*^*−/−*^ mutant background as well as in the Sb-resistant *mrpA*^*−/−*^ clones and establish whether this correlates with specific changes in sensitivity to Sb^III^.

Amplification of MRPA or loss-of-function mutations in AQP1 are the primary mechanisms of Sb resistance in both laboratory and field isolates ([@bib32]; [@bib9]; [@bib20]). That said, these strong traits could preclude the identification of secondary mechanisms/markers of drug resistance against Sb. In oder to evaluate the occurrence of SNPs in the *sat* gene in clinical isolates, the TritrypDB [database](tritrypdb:database){#intref0025} ([@bib2]) was mined for genetic variations in the *sat* gene among its *L. donovani* datasets, which comprise a total of 252 isolates. Six non-synonymous polymorphisms were found (lines 234,631 to 264,639 highlighted in yellow in the Ldono_allTritryp_SNPs tab of Dataset 4). The strains harboring the changes were retrieved from a nucleotide alignment of the *sat* gene for the 252 isolates (tab strains of Dataset 4). Most of the strains including SNPs in the *sat* gene are associated with a dataset derived from a study of Ethiopian *L. donovani* ([@bib56]). However, Zackay and co-workers only explored the drug-resistant profile of these strains against methotrexate because they were able to identify CNVs for the folate transporter in most of the Northeast strains ([@bib56]). On the other hand, some strains with polymorphism in the *sat* gene are part of the Indian-sucbontinent cluster 1 (ISC1) identified by Imamura and co-workers ([@bib20]). Intriguingly, intra-chromosomal amplification of *mrpA* was present in all core population isolates but was absent in ISC1. It would be interesting to address whether the presence of mutations in the *sat* gene in the absence of duplication of *mrpA* is affecting the sensitivity of ISC1 strains. Additional work may indicate whether these mutations in the *sat* gene are directly related to Sb selection, and treatment failure, or simply provide a general fitness gain that allows the parasite to survive in stressful conditions.

5. Conclusion {#sec5}
=============

In this study, we combined targeted gene disruption, stepwise drug-resistance selection, and NGS in *L. infantum* to search for novel Sb-resistance mechanisms deployed by the parasite when ABC transporter MRPA is abolished. We demonstrated that MRPA is not essential for survival of *Leishmania*, and its disruption does not impair the parasite\'s infectivity. Furthermore, we revealed major changes in the karyotype and CNVs of the subtelomeric region of chromosome 23 in our five *mrpA* null mutants exposed to increasing concentrations of Sb. Our results reinforce and expand knowledge on the complex nature of Sb resistance in *Leishmania* by highlighting two previously unreported Sb-resistance related genes, *sat* and *ABCC2*, which are putatively linked to thiol biosynthesis and transport in these parasites. These findings could have a significant positive impact on the control of this critical zoonotic disease.

Declaration of competing interest
=================================

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data {#appsec1}
==============================

The following are the Supplementary data to this article:Multimedia component 1Multimedia component 1Supplementary Figure S1**Genome-wide distribution of SNPs in *L. infantum mrpA***^**-/-**^**mutants selected for antimony resistance.** Bars represent the genes on each chromosome. Colored bars represent genes mutated in defined numbers of mutant clones; gray bars represent non-mutated genes. Source data are provided as Dataset S3.Multimedia component 2Multimedia component 2Supplementary Figure S2**Genes mutated in two or more *L. infantum mrpA***^**-/-**^**mutants.** In this matrix, a green-colored square indicates the presence of the mutation in the mutant, an empty square means indicates the absence of the SNP in the mutant. The last column indicates the total number of mutants into which the gene was mutated.Multimedia component 3Multimedia component 3Multimedia component 4Multimedia component 4Multimedia component 5Multimedia component 5
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